Table 3.
MRI findings | One-Stop pathway (n=74) | Standard pathway (n=296) | p-value |
---|---|---|---|
PI-RADS 1–2 (n=107) | 23 | 84 | |
PCa | 11 (48%) | 28 (33%) | 0.2 |
csPCa | 5 (22%) | 14 (17%) | 0.55 |
PI-RADS 3–5 (n=263) | 51 | 212 | |
PCa | 34 (67%) | 126 (59%) | 0.20 |
csPCa | 25 (49%) | 87 (41%) | 0.55 |
PI-RADS 3 (n=200) | 36 | 164 | |
PCa | 20 (56%) | 88 (54%) | 0.84 |
csPCa | 12 (33%) | 54 (33%) | 0.96 |
PI-RADS 4 (n=39) | 8 | 31 | |
PCa | 7 (88%) | 24 (77%) | 0.53 |
csPCa | 6 (75%) | 20 (65%) | 0.57 |
PI-RADS 5 (n=24) | 7 | 17 | |
PCa | 7 (100%) | 14 (82%) | 0.23 |
csPCa | 7 (100%) | 13 (76%) | 0.16 |
PCa, prostate cancer; csPCa, clinically significant PCa; MRI, magnetic resonance imaging; n= number of patients; PI-RADS, Prostate Imaging and Reporting Data System.